Stereotactic Ablative Radiotherapy for Cancer
(SABR-COMET Trial)

Recruiting in Palo Alto (17 mi)

+9 other locations

Dr. David Palma - Ontario Institute for ...

Overseen bySuresh Senan, MRCPFRCR,PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?Stereotactic Ablative Radiotherapy (SABR) is a new radiation treatment that delivers high-dose, precise radiation to small tumors in 1-3 weeks of treatment. This new technique can potentially allow radiation treatments to be focused more precisely, and delivered more accurately than with older treatments. This improvement could help by reducing side effects and by improving the chance of controlling the cancer by more precisely treating the cancer. The purpose of this study is to compare SABR with current approaches of chemotherapy and conventional radiotherapy to assess the impact on overall survival and quality of life.

Eligibility Criteria

This trial is for adults over 18 with a life expectancy of more than 6 months and confirmed metastatic cancer. They should have had no systemic therapy in the month before radiotherapy, be able to consent, and have an ECOG performance status of 0-1. All cancer sites must be treatable with SABR, which excludes those with certain brain or bone metastases or previous treatments like surgery that can't be followed by SABR.

Inclusion Criteria

I haven't had any cancer treatment in the last 4 weeks.

My treated cancer spread is under control, or if not, it can be treated with SABR after surgery.

Willing to provide informed consent

+9 more

Exclusion Criteria

I have health conditions that prevent me from receiving radiotherapy.

I have 1-3 brain tumors and no cancer in other parts of my body.

I have had radiation therapy on the area that now needs treatment.

+7 more

Participant Groups

The study compares Stereotactic Ablative Radiotherapy (SABR), a precise high-dose radiation treatment given over 1-3 weeks, to conventional chemotherapy and radiotherapy. It aims to see if SABR offers better control of cancer with fewer side effects, thus improving survival rates and quality of life.

2Treatment groups

Experimental Treatment

Active Control

Group I: Stereotactic armExperimental Treatment1 Intervention

Stereotactic ablative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist

Group II: Standard armActive Control1 Intervention

Standard of care, palliative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist